NCT07015697
A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Aug 30, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
All 9 versions: 9 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Enrollment closed, study ongoing
- Final enrollment: 17 participants (planned 76)
- Notable Eligibility criteria shortened, about 469 words
- Trial sites expanded: 26 → 31 locations
- Minor Study sites: 23 to 26v8
- Notable Eligibility criteria shortened, about 22 wordsv7
- Minor Study sites: 13 to 23v6
Show 4 earlier versionsHide 4 earlier versions
- Minor Study sites: 5 to 13v5
- Minor Study sites: 2 to 5
- Start date changed from estimate of Aug 29, 2025 to Jul 17, 2025
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 2
- Notable Start date: Jun 30, 2025 to Aug 29, 2025
- Eligibility criteria expanded, about 45 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (3)
Arms and interventions
Participants will receive Trastuzumab Deruxtecan subcutaneously at escalating doses. The recommended dose for expansion (RDE) will be calculated using data collected from this population.
Participants will receive Trastuzumab Deruxtecan subcutaneously at the recommended dose for expansion (RDE)
Drugs: Trastuzumab Deruxtecan
Sites
31 sites in 7 countries
United States 6, Brazil 5, Japan 5, South Korea 5, Taiwan 5, Spain 3, France 2